A potential means to help the HPV vaccine penetrate the Japanese public while under the continued suspension of governmental recommendation

Ugumori, Natsuyo; Ueda, Yutaka; Yagi, Akira; Abe, Hirotake; Shiomi, Mayu; Nakagawa, Satoshi; Hiramatsu, Kosuke; Miyoshi, Anderson; Kobayashi, Eiji; Kimura, Toshihiro; Kimura, Tadashi; Nabeta, Motowo

doi:10.1080/21645515.2021.1910001

Cited by 7 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have found that, even under the suspension of governmental recommendation, if their family doctor provided information using an information leaflet explaining the need for cervical cancer prevention, that act led to an increase in the number of vaccinations [42]. Among the 53 mothers who said they would impose certain preconditions before being willing to encourage their daughters' HPV vaccination, 21 (39.6%) became more willing to vaccinate their daughters immediately after receiving such an explanation.…”

Section: After a Resumption Of The Governmental Recommendation?mentioning

confidence: 91%

Cervical Cancer Protection in Japan: Where Are We?

et al. 2021

Self Cite

View full text Add to dashboard Cite

In Japan, government subsidies for human papillomavirus (HPV) vaccination of girls aged 13–16 commenced in 2010. By early 2013, vaccination had become a widely accepted national immunization program. However, in June of 2013, the Ministry of Health, Labor, and Welfare (MHLW), the government’s lead agency, suspended its recommendation for vaccination in response to reports of adverse vaccine events. The rate of HPV vaccination quickly dropped from 70% to almost zero, where it has lingered for eight years. In 2020, a new 9-valent HPV vaccine was licensed in Japan. The momentum seemed to be building for the resumption of HPV vaccinations, yet Japanese mothers remain widely hesitant about vaccinating their daughters, despite the well-proven safety and efficacy of the HPV vaccines. The Japanese government and our educational and medical institutions must work harder as a team to inform our parents and their children about the life-saving benefits of the HPV vaccine, and at the same time, we must respond to all their concerns and questions. The vaccine hesitancy of unvaccinated women born in 2000 and thereafter is a natural consequence of the suspension of the government‘s recommendation. We must also take every possible measure to reduce the significant risk for cervical cancer these women have.

show abstract

Section: After a Resumption Of The Governmental Recommendation?mentioning

confidence: 91%

Cervical Cancer Protection in Japan: Where Are We?

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, multiple local education programs about the HPV vaccination have been conducted for the past several years. [7][8][9] In response to these efforts, the attitudes and understanding of people who are eligible for vaccination are also gradually changing. 10 The majority of AEs reported between 2016 and 2018 were linked to HPV immunizations administered before the period when the AEs were reported.…”

Section: Lettermentioning

confidence: 99%

“…In addition, multiple local education programs about the HPV vaccination have been conducted for the past several years. 7–9 In response to these efforts, the attitudes and understanding of people who are eligible for vaccination are also gradually changing. 10 …”

Section: Lettermentioning

confidence: 99%

Changing trends in HPV vaccination in Japan

Ujiie

Kitano

Tsuzuki

2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

After the Japanese Ministry of Health, Labor and Welfare (MHLW) suspended its recommendation for the human papillomavirus (HPV) vaccine in June 2013, the rate of members of the new target population receiving of at least one of three doses of HPV vaccine declined, reaching 0.3% in 2016. Recently, however, the monthly number of vaccines delivered to healthcare facilities has significantly increased, from 878 doses over December 2016-April 2017 to 35,396 doses over January-March 2021. This may be due to governmental efforts to convey information about the HPV vaccination to the eligible population and their caregivers, as well as local educational programs, despite ongoing suspension of the recommendation. The incidence of reported adverse events per vaccine dose has not increased since 2016. While governmental recommendation of the HPV vaccination remains essential for optimal vaccine coverage, the recent increase in the number of doses delivered to healthcare facilities is promising.

show abstract

“…clinic returned to the clinic immediately to get their daughters vaccinated (21). We believe that the family doctor has a major influence on vaccination decisions.…”

mentioning

confidence: 99%

The Chasm We Must Cross in Japan for Re-promotion of the HPV Vaccine

Ueda

Katayama

Yagi

et al. 2021

Cancer Prevention Research

Self Cite

View full text Add to dashboard Cite

In Japan, the human papillomavirus (HPV) vaccination rate has decreased from around 70% to less than 1% due to repeated media reports of diverse symptoms after HPV vaccination, and to suspension of the governmental recommendation. The challenges for re-promotion of the vaccine will be discussed from a marketing perspective. The adopter categories by which a new product penetrates the market can be divided into five groups, including Innovators, Early adopters, Early majority, Late majority, and Laggards. The 16.0% line, which is the sum of the percentages of the innovators and the early adopters, is thought to be

show abstract

A potential means to help the HPV vaccine penetrate the Japanese public while under the continued suspension of governmental recommendation

Cited by 7 publications

References 14 publications

Cervical Cancer Protection in Japan: Where Are We?

Cervical Cancer Protection in Japan: Where Are We?

Changing trends in HPV vaccination in Japan

The Chasm We Must Cross in Japan for Re-promotion of the HPV Vaccine

Contact Info

Product

Resources

About